Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301366 | 0.82 | CYP1A2 (0.46) | BRD4CYP1A2HIF1AALDH1A1MMP2 | |
| SCHEMBL10887665 | 0.78 | ALDH1A1 (0.52) | BRD4CYP1A2HIF1AALDH1A1KMT2A | |
| SCHEMBL16494534 | 0.77 | BRD4 (0.44) | BRD4CYP1A2HIF1AALDH1A1MMP2 | |
| SCHEMBL3214008 | 0.77 | BRD4 (0.37) | BRD4CYP1A2HIF1AALDH1A1KMT2A | |
| SCHEMBL5400138 | 0.75 | CHRM2 (0.45) | CYP1A2ALDH1A1KMT2ACYP2C19 | |
| Methyl Alcohol SCHEMBL7022791 | 0.75 | BRD4 (0.36) | BRD4CYP1A2HIF1AALDH1A1KMT2A | |
| SCHEMBL1521223 | 0.73 | BRD4 (0.38) | BRD4CYP1A2HIF1AALDH1A1MMP2 | |
| SCHEMBL1238701 | 0.73 | BRD4 (0.42) | BRD4CYP1A2HIF1AALDH1A1MMP2 | |
| SCHEMBL2786795 | 0.73 | BRD4 (0.38) | BRD4CYP1A2HIF1AALDH1A1MMP2 | |
| SCHEMBL3628762 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725420-B2 | Processes | GLAXO GROUP LIMITED (GB) | 2017-08-08 | — | — | US | claimed |
| US-20160347720-A1 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2016-12-01 | — | — | US | claimed |
| US-20250312504-A1 | VOLATILE COMPOSITION DISPENSER FOR COMPOSITIONS COMPRISING A META-(C1-C4 ALKOXY) SALICYLALDEHYDE | THE PROCTER & GAMBLE COMPANY | 2025-10-09 | — | — | US | disclosed |
| US-20240336868-A1 | COMPOSITIONS COMPRISING ADAMANTYL ESTER-CONTAINING COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2024-10-10 | — | — | US | disclosed |
| US-20240199997-A1 | COMPOSITIONS COMPRISING A META-(C1-C4 ALKOXY) SALICYLALDEHYDE | PROCTER & GAMBLE COMPANY, THE | 2024-06-20 | — | — | US | disclosed |
| EP-2571857-B1 | PROCESS FOR THE PREPARATION OF PYRIMIDINONE COMPOUNDS | GLAXO GROUP LTD (GB) | 2017-08-23 | — | — | EP | disclosed |
| US-9725420-B2 | Processes | GLAXO GROUP LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-20160347720-A1 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2016-12-01 | — | — | US | disclosed |
| US-9447052-B2 | Processes for preparing pyrimidine compounds | GLAXO GROUP LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| EP-2571857-A1 | NOVEL PROCESSES | Glaxo Group Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-20130060028-A1 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | US | disclosed |
| WO-2011146494-A1 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060028-A1 | NOVEL PROCESSES | CYP11B1, CYP27A1, CYP11B2 | BRD4 1644/4885CYP1A2 217/4885HIF1A 189/4885 |
| US-20160347720-A1 | NOVEL PROCESSES | CYP11B1, CYP27A1, CYP11B2 | BRD4 1644/4885CYP1A2 217/4885HIF1A 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.